BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 26401581)

  • 1. LESSONS FROM 50 YEARS OF STUDY OF LARON SYNDROME.
    Laron Z
    Endocr Pract; 2015 Dec; 21(12):1395-402. PubMed ID: 26401581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fifty seven years of follow-up of the Israeli cohort of Laron Syndrome patients-From discovery to treatment.
    Laron Z; Kauli R
    Growth Horm IGF Res; 2016 Jun; 28():53-6. PubMed ID: 26307357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Laron syndrome - A historical perspective.
    Laron Z; Werner H
    Rev Endocr Metab Disord; 2021 Mar; 22(1):31-41. PubMed ID: 32964395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A half-century of studies of growth hormone insensitivity/Laron syndrome: A historical perspective.
    Rosenbloom AL
    Growth Horm IGF Res; 2016 Jun; 28():46-50. PubMed ID: 26276451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Congenital IGF-1 deficiency protects from cancer: lessons from Laron syndrome.
    Laron Z; Werner H
    Endocr Relat Cancer; 2023 Sep; 30(9):. PubMed ID: 37343154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and Molecular Features of Laron Syndrome, A Genetic Disorder Protecting from Cancer.
    Janecka A; Kołodziej-Rzepa M; Biesaga B
    In Vivo; 2016; 30(4):375-81. PubMed ID: 27381597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IGF-I deficiency, longevity and cancer protection of patients with Laron syndrome.
    Laron Z; Kauli R; Lapkina L; Werner H
    Mutat Res Rev Mutat Res; 2017; 772():123-133. PubMed ID: 28528685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in plasma amino acids metabolites, caused by long-term IGF-I deficiency, are reversed by IGF-I treatment - A pilot study.
    Barazani C; Werner H; Laron Z
    Growth Horm IGF Res; 2020 Jun; 52():101312. PubMed ID: 32200226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Head circumference in untreated and IGF-I treated patients with Laron syndrome: comparison with untreated and hGH-treated children with isolated growth hormone deficiency.
    Laron Z; Iluz M; Kauli R
    Growth Horm IGF Res; 2012 Apr; 22(2):49-52. PubMed ID: 22414926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term auxological and pubertal outcome of patients with hereditary insulin-like growth factor-I deficiency (Laron and growth hormone-gene deletion syndrome) treated with recombinant human insulin-like growth factor-I.
    Messina MF; Arrigo T; Valenzise M; Ghizzoni L; Caruso-Nicoletti M; Zucchini S; Chiabotto P; Crisafulli G; Zirilli G; De Luca F
    J Endocrinol Invest; 2011 Apr; 34(4):292-5. PubMed ID: 20543555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and biological function of the female gonads and genitalia in IGF-I deficiency -- Laron syndrome as a model.
    Laron Z
    Pediatr Endocrinol Rev; 2006 Jan; 3 Suppl 1():188-91. PubMed ID: 16641857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonalcoholic fatty liver in patients with Laron syndrome and GH gene deletion - preliminary report.
    Laron Z; Ginsberg S; Webb M
    Growth Horm IGF Res; 2008 Oct; 18(5):434-438. PubMed ID: 18462969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IGF-I replacement therapy in children with congenital IGF-I deficiency (Laron syndrome) maintains heart dimension and function.
    Scheinowitz M; Feinberg MS; Laron Z
    Growth Horm IGF Res; 2009 Jun; 19(3):280-2. PubMed ID: 19117781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin-like growth factor-I treatment of children with Laron syndrome (primary growth hormone insensitivity).
    Laron Z
    Pediatr Endocrinol Rev; 2008 Mar; 5(3):766-71. PubMed ID: 18367997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fanconi Anemia and Laron Syndrome.
    Castilla-Cortazar I; de Ita JR; Aguirre GA; Castorena-Torres F; Ortiz-Urbina J; García-Magariño M; de la Garza RG; Diaz Olachea C; Elizondo Leal MI
    Am J Med Sci; 2017 May; 353(5):425-432. PubMed ID: 28502327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel growth hormone receptor gene mutation in a patient with Laron syndrome.
    Arman A; Yüksel B; Coker A; Sarioz O; Temiz F; Topaloglu AK
    J Pediatr Endocrinol Metab; 2010 Apr; 23(4):407-14. PubMed ID: 20583548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hand size and growth in untreated and IGF-I treated patients with Laron syndrome.
    Konen O; Silbergeld A; Lilos P; Kornreich L; Laron Z
    J Pediatr Endocrinol Metab; 2009 Mar; 22(3):235-9. PubMed ID: 19492579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Foot length before and during insulin-like growth factor-I treatment of children with laron syndrome compared to human growth hormone treatment of children with isolated growth hormone deficiency.
    Silbergeld A; Lilos P; Laron Z
    J Pediatr Endocrinol Metab; 2007 Dec; 20(12):1325-8. PubMed ID: 18341092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA 132-3p Is Upregulated in Laron Syndrome Patients and Controls Longevity Gene Expression.
    Yaron-Saminsky D; Nagaraj K; Sarfstein R; Laron Z; Pasmanik-Chor M; Werner H
    Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical features and growth hormone receptor gene mutations of patients with Laron syndrome from a Chinese family.
    Ying YQ; Wei H; Cao LZ; Lu JJ; Luo XP
    Zhongguo Dang Dai Er Ke Za Zhi; 2007 Aug; 9(4):335-8. PubMed ID: 17706034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.